Metformin-associated lactic acidosis: Current perspectives on causes and risk.
DeFronzo R, Fleming GA, Chen K, Bicsak TA.
Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9.
Metformin: When Should We Fear Lactic Acidosis?
Di Mauro S, Filippello A, Scamporrino A, Purrello F, Piro S, Malaguarnera R.
Int J Mol Sci. 2022 Jul 28;23(15):8320. doi: 10.3390/ijms23158320.
Metformin-associated lactic acidosis.
Fadden EJ, Longley C, Mahambrey T.
BMJ Case Rep. 2021 Jul 8;14(7):e239154. doi: 10.1136/bcr-2020-239154.
Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK.
JAMA. 2014 Dec 24-31;312(24):2668-75. doi: 10.1001/jama.2014.15298.
Metabolic acidosis.
Lim S.
Acta Med Indones. 2007 Jul-Sep;39(3):145-50.
Lactic Acidosis Associated with Metformin in Patients with Diabetic Kidney Disease.
Rahman F, Tuba S.
Med Arch. 2022 Aug;76(4):297-300. doi: 10.5455/medarh.2022.76.297-300.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE.
Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD002967. doi: 10.1002/14651858.CD002967.pub4.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE.
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD002967. doi: 10.1002/14651858.CD002967.pub3.
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Theurey P, Vial G, Fontaine E, Monternier PA, Fouqueray P, Bolze S, Moller DE, Hallakou-Bozec S.
Physiol Rep. 2022 Mar;10(5):e15151. doi: 10.14814/phy2.15151.
Lactic acidosis in patients with diabetes.
Krzymień J, Karnafel W.
Pol Arch Med Wewn. 2013;123(3):91-7. doi: 10.20452/pamw.1619. Epub 2013 Jan 8.
